Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results
By
The Pink Sheet Daily / Email the Author / “The Pink Sheet” DAILY Jul. 28, 2010
Word Count: 877 / Article # 14100728006
Executive Summary
FDA's Cardiovascular and Renal Drugs Advisory Committee votes 7-1 in favor of ticagrelor's approval for acute coronary syndromes despite rejecting AstraZeneca's aspirin-dosing theory as the sole cause of lack of benefit in the U.S. population.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.